Product Images Atorvaliq

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Atorvaliq NDC 46287-030 by Cmp Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Effect of Atorvastatin 10 mg/day on Cumulative Incidence of Non-Fatal Myocardial Infarction or Coronary Heart Disease Death (in ASCOT-LLA) - image 02

Effect of Atorvastatin 10 mg/day on Cumulative Incidence of Non-Fatal Myocardial Infarction or Coronary Heart Disease Death (in ASCOT-LLA) - image 02

This appears to be a graph showing the cumulative incidence of something over time, possibly a medical study or clinical trial. There are percentages listed on the y-axis and years on the x-axis. The values on the y-axis start at 15 and go up to 40. There is also a line labeled "HR-084" with a value of 25 at the 5-year mark. A p-value of 0.0005 is listed.*

Effect of Atorvastatin 10 mg/day on Time to Occurrence of Major Cardiovascular Event (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) in CARDS - image 03

Effect of Atorvastatin 10 mg/day on Time to Occurrence of Major Cardiovascular Event (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) in CARDS - image 03

Effect of Atorvastatin 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT) - image 04

Effect of Atorvastatin 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT) - image 04

The text is a table showing the percentage of subjects who experienced an event for two different medications: Aorvastatin 10 mg and Aorvastatin 80 mg. It also includes an HR (hazard ratio) value and the p-value for the comparison between the two medications. The table also shows the time to the first major cardiovascular endpoint in years.*

Chemical Structure - spl 01

Chemical Structure - spl 01

PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label - spl 05

PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label - spl 05

Recommended dosage information for Atorvastatin (calcium equivalent to 4mg per mL) oral suspension is available in the Praseribing Information. The oral suspension comes in a 150mL bottle and should be stored at controlled room temperature. The suspension must be shaken well before use and should be consumed within 60 days of opening. Dispensing to patients should be done in the original packaging. This text also includes lot number and expiration date information but due to errors, some characters are not readable.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.